Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind placebo-controlled study of brexpiprazole adjunctive therapy in major depressive disorder
CTR20180335Phase 3Suspended
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of brexpiprazole in major depressive disorder (MDD), sponsored by Otsuka Pharmaceutical Co., Ltd.. Started May 2018; status: suspended.
02
Drugs
brexpiprazole
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on CTR20180335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180335.